CLOV vs WKHS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 18, 2026

CLOV

40.9
AI Score
VS
CLOV Wins

WKHS

37.4
AI Score

Investment Advisor Scores

CLOV

41score
Recommendation
HOLD

WKHS

37score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric CLOV WKHS Winner
Forward P/E 37.7358 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 55.6% 374.9% WKHS
Earnings Growth 0.0% 19043.5% WKHS
Tradestie Score 40.9/100 37.4/100 CLOV
Profit Margin -0.7% -289.0% CLOV
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY CLOV

Relative Price Performance (Last 90 Days)

CLOV 1M: +3.2% · 3M: +9.1% WKHS 1M: -13.0% · 3M: -3.0%

Current Technical Phase

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 54

RSI (14): 54.3 · Price: $4.72

WKHS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.9%), weak momentum, RSI 32

RSI (14): 32.2 · Price: $2.63

Fundamentals Snapshot

Metric CLOV WKHS
Market Cap — —
Forward P/E 31.5 -1.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.6% 3.7%
Gross Margin 0.2% -0.8%
Operating Margin 0.0% -5.5%
EPS -0.05 -6.61
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLOV is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.